WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company today announced the completion of a second pancreatic clinical trial of BrachySil™ (P32 BioSilicon™), a potential new brachytherapy treatment for inoperable pancreatic cancer. Six patients were studied at two centers in the UK (Guy’s and St Thomas’ NHS Foundation Trust and University Hospital, Birmingham). The study was conducted to determine the safety of escalating radiation doses of the BrachySil™ device and to determine an optimum dosing level. Tumor response was also measured as a secondary end point.
